3.8 Article

PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

Journal

PAIN MANAGEMENT
Volume 11, Issue 6, Pages 647-654

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/pmt-2021-0015

Keywords

adherence; calcitonin gene-related peptide; chronic; episodic; fremanezumab; migraine; persistence; real world

Funding

  1. Teva Pharmaceuticals Europe BV

Ask authors/readers for more resources

Fremanezumab is an injectable biologic medication used for preventing migraine attacks, with the main goals of reducing migraine days and disability, evaluating patient adherence to treatment plans, and assessing treatment discontinuation.
Lay abstract: Fremanezumab is an injectable biologicmedication that targets calcitonin gene-related peptide, a substance released in the nerves and blood vessels during a migraine attack that plays a role in migraine pain. Fremanezumab is approved in Europe for preventing migraine in adults who experience >= 4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month long study that will observe patients with migraine who are starting treatment with fremanezumab in a clinical practice setting under the care of their treating physician. The major goals of the study are to evaluate the effectiveness of fremanezumab for reducing days with migraine attacks in a month, disability associated with migraine and use of acute headache medications to treat migraine, including in patients switching from other biologic migraine therapies in the same drug class. The extent to which patients follow their recommended treatment schedule per their providers' instructions and whether patients discontinue treatment will also be evaluated. The PEARL study will include >1000 patients in 100 centers across 11 European countries. The study will provide important information on effectiveness for patients with migraine receiving fremanezumab in the normal course of their treatment, as well as on patients' use of fremanezumab according to their prescribing physicians' recommendations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available